BMS to acquire Forbius in oncology expansion
Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.
Amgen urges Fed Circuit to deny Sandoz petition
Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
Teva charged in DoJ antitrust probe into generic drug price-fixing
Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.
Intercept sues Apotex over Ocaliva generic
Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Spruson & Ferguson promotes four to principal
Law firm Spruson & Ferguson has appointed four new principals across the firm as part of its 2020 promotions. The appointments have been made in the firm’s Hong Kong, Singapore, Sydney and Melbourne offices.
Ferring wins Nocdurna patent suit with ex-employee
Swiss-based Ferring Pharmaceuticals has prevailed in a patent dispute with rivals Serenity Pharmaceuticals and Reprise Biopharmaceuticals over a nighttime urination, or nocturia, treatment.
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
LSPN Connect: CRISPR technologies
In an LSPN Connect session, Millipore’s senior corporate patent counsel, Ben Sodey, and head of legal and IP at Arbor, Kelly Morgan, shared their insights on the latest developments in this area of gene editing technology.
Judge issues mixed ruling on Shkreli attorney communications
The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.
Sandoz gains backing for Enbrel patent term review
Sandoz has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel until 2029.
